Tumor DNA and protein testing to understand pancreatic cancer treatment response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study collects tumor tissue, fluid, and blood from adults with resectable, borderline resectable, or locally advanced pancreatic ductal adenocarcinoma who are enrolled in the Personalized Oncogenomics (POG) Program at BC Cancer. Participants receive standard chemotherapy and may undergo optional biopsy or tissue collection during laparoscopy, with samples analyzed for tumor DNA and protein markers. The study measures whether genomic and proteomic results can be returned in a timeframe that could inform treatment decisions and whether those results predict response or resistance to therapy. Clinic visits occur every four weeks and participants complete questionnaires every 12 weeks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants must meet all of the following criteria prior to Pre-Baseline registration:

1. Age 18 years or older.
2. Histological or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC.
3. Medically fit and planned to undergo laparoscopic procedure as part of standard of care.
4. Able to give informed consent for the study-related procedures performed during laparoscopy.

Participants must meet all of the following criteria to be eligible for enrollment in the Main Study:

1. Age 18 years or older.
2. Enrolled in the Personalized Oncogenomics (POG) Program at BC Cancer.
3. Histological and/or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC. Participants without a histological diagnosis of PDAC must undergo confirmatory histological diagnosis prior to treatment start date.
4. Medically fit to undergo surgical resection of the primary lesion(s) as judged by the investigator (Resectable and Borderline Resectable Cohorts only).
5. Planned for adjuvant (Resectable and Borderline Resectable Cohorts) or first-line (Locally Advanced Cohort) therapy with FOLFIRINOX or a gemcitabine-based regimen, either as part of routine care or in combination with an investigational agent(s) within another clinical trial. Participants may have received pre-operative therapy.
6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
7. Adequate organ function as defined by the following laboratory results obtained within 28 days prior to enrollment date:

   1. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L.
   2. Hemoglobin ≥ 9 g/dL.
   3. Platelets ≥ 75 x 10\^9/L.
   4. Prothrombin time test and international normalized ratio (PT/INR) and partial thromboplastin time (PTT) ≤ 1.5 x Upper Limit of Normal (ULN).
   5. Total bilirubin ≤ 1.5 x ULN. Isolated bilirubin \> 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%.
   6. Aspartate aminotransferase (AST) and alanine aminotransferase (AST) ≤ 1.5 x ULN. If liver metastases are present, AST and ALT ≤ 5 x ULN is permitted.
   7. Albumin ≥ 25 g/L.
   8. One of the following:

      * Creatinine ≤ 1.5 x ULN.
      * Calculated creatinine clearance (as calculated by Cockcroft-Gault formula) ≥ 40 mL/min.
      * 24-hour urine creatinine clearance ≥ 40 mL/min.
8. Life expectancy greater than 90 days as judged by the investigator.
9. Able to give informed consent for the study procedures defined in this protocol.
10. Measurable disease by RECIST 1.1. For those in the Resectable and Borderline Resectable Cohorts, measurable disease must be present prior to resection surgery.

Exclusion Criteria:

1. Presence of distant or lymph node metastases. Individuals with metastatic PDAC are not eligible.
2. Currently receiving adjuvant (Resectable and Borderline Resectable Cohorts) or systemic (Locally Advanced Cohort) anti-cancer therapy (chemotherapy or any other anti-cancer agent) with one exception: pre-operative therapy is permitted.
3. Not fit for chemotherapy as judged by the investigator.
4. Presence of brain metastases.
5. Positive pregnancy test.
6. Unable to comply with the study assessments and procedures defined in this protocol.
7. Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol.

Where it's running

• BC Cancer
  Vancouver, British Columbia, Canada Recruiting

Study contacts

• Principal investigator: Daniel J Renouf, MD — BC Cancer
• Study coordinator: Daniel J Renouf, MD
• Email: drenouf@bccancer.bc.ca
• Phone: 800-663-3333

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Samuraciclib given before surgery or chemotherapy for certain pancreatic cancers

  This study tests whether taking samuraciclib before standard treatment is safe and helps patients with localized pancreatic cancer.

  Recruiting Phase 1 University of Washington · Seattle, Washington · NCT07645651

• Targeted therapy for pancreatic cancer using new drugs

  This study is testing new targeted therapies for pancreatic cancer to see how well they work and if they are safe for patients at different stages of the disease.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT04005690

• SMAD4-tailored neoadjuvant therapy for pancreatic cancer that can be surgically removed

  This trial tests whether using SMAD4 mutation status can guide pre-surgery chemotherapy for patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT07748611

• PULSAR personalized ultrafractionated adaptive proton radiotherapy combined with systemic therapy for pancreatic cancer

  This trial will test whether personalized PULSAR proton radiotherapy given after initial chemotherapy can improve local control for people with borderline resectable, locally advanced, or limited metastatic pancreatic cancer.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Select Province/State · NCT07269626

• Using advanced MRI to assess treatment response in pancreatic cancer

  This study is testing a new MRI technique to see if it can better predict how well treatment works for people with pancreatic cancer.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06600906

• Exploring how diet and gut bacteria affect chemotherapy response in pancreatic cancer

  This study is testing how diet and gut bacteria affect how well people with pancreatic cancer respond to chemotherapy.

  Recruiting Emory University · Atlanta, Georgia · NCT06595160

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.